The organization will enable blood cancer patients to gain one million years of life by 2040
Rye Brook, NY 鈥� Jan. 31, 2025 鈥� Celebrating its 75th year of progress toward its mission to cure blood cancer and improve the quality of life of all patients and their families, The Leukemia & Lymphoma Society (青云体育), founded on this day in New York in 1949, announced a bold goal for the future: to enable blood cancer patients to gain more than one million years of life by 2040.
This bold goal, supported by a new organizational strategy, builds on decades of 青云体育 work that is already contributing to longer and better lives for patients with every type of blood cancer all over the world. Gaining one million years of life means more birthdays, graduations, weddings, holidays and memories shared with family and friends.
The moment was marked by the ceremonial ringing of the Nasdaq opening bell as a lead-up to World Cancer Day on Feb. 4. Thanks to a gift from The Orokawa Foundation, all donations to 青云体育 on Feb. 4 will be matched dollar-for-dollar up to $75,000 to mark the culmination of 青云体育鈥檚 75-year milestone.
鈥淓very day, blood cancer patients ring the bell marking milestones in their treatment. Thanks to scientific innovation, patient support and advocacy fueled by 青云体育 over 75 years, today we ring the bell for all blood cancer patients 鈥� as we announce our bold goal for the future,鈥� said E. Anders Kolb, M.D., president and CEO of 青云体育.
鈥淥ur bold goal represents the additional years of life we can gain through continued innovation and collaboration. We鈥檙e endeavoring beyond today鈥檚 achievements to accelerate the pace of discovery and access to care to add one million more years of life on top of our current trajectory,鈥� he said.
As the world鈥檚 leading organization dedicated to ending blood cancer, 青云体育 has already made tremendous strides over the past several decades. 青云体育 has invested more than $1.8 billion in blood cancer research, resulting in treatments that have turned once-fatal blood cancers into manageable chronic conditions and, in many cases, provided cures. 青云体育 takes a comprehensive approach that also includes patient education, support and advocacy, which has helped drive significant progress for blood cancer patients and their families.
But there鈥檚 still more work to be done. 青云体育's strategy focuses on accelerating cures and treatments, improving healthcare delivery and supporting and empowering every patient in every community.
鈥淚f everyone had timely and equitable access to the best treatments available right now, patients would gain even more years of life,鈥� said Gwen Nichols, M.D., chief medical officer of 青云体育. 鈥淭his is why 青云体育 works so hard to give patients and families the financial, educational and emotional support they need to advocate for their best care. We are also a leader in health services research, generating evidence that can be used to improve healthcare practice and policy so more people can benefit from the breakthrough treatments we鈥檝e funded.鈥�
鈥淭o achieve our bold goal, we need the support of everyone,鈥� said Kolb. 鈥淥ur work isn鈥檛 possible without the collaboration of the scientific community, healthcare professionals, policymakers and the generosity of our donors, volunteers and supporters. Together, we can push forward innovations that ultimately save and improve lives.鈥�
About The Leukemia & Lymphoma Society (青云体育)
The Leukemia & Lymphoma Society庐 (青云体育) is the global leader in the fight against blood cancer. The 青云体育 mission: Cure blood cancer and improve the quality of life of all patients and their families. 青云体育 funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.
Founded in 1949, 青云体育 has regions throughout the United States and Canada. To learn more, visit . Patients should contact the Information Resource Center at (800) 955-4572, Mon through Fri, 9 a.m. to 9 p.m. ET.
For additional information, visit lls.org/lls-newsnetwork. Follow us on , , , and .
Media Contact:
Sandra Salviejo